Rapport Therapeutics, Inc. RAPP
25.96 USD -0.11 (-0.42%)
At closeNov 11, 2026, 4:01 AM EST
26.00 +0.04 +0.15%
Pre-market · Nov 11, 4:01 AM ET
25.30 Day range 26.90
22.06 52-week range 52.93
- YTD
- -14.44%
- 1 year
- +1.80%
News
benzinga.com UBS Maintains Buy on Rapport Therapeutics, Lowers Price Target to $64 UBS analyst Joon Lee maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $71 to $64.- benzinga.com Guggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66 Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $70 to $66.
benzinga.com Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $47 Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $50 to $47.
benzinga.com Rapport Therapeutics Q3 EPS $(0.84) Beats $(1.19) Estimate Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.19) by 29.41 percent. This is a 18.31 percent decrease over losses…
globenewswire.com Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label long-term safety…- benzinga.com Rapport Therapeutics Closes Underwritten Public Offerings Of 9,761,905 Shares At $21.00 Per Share Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…
benzinga.com Enphase Energy Posts Downbeat Q3 Results, Joins NXP Semiconductors, Seagate And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures mixed as Enphase plunges 17% after earnings and weak guidance; Rapport, Intapp, Logitech and others also fall premarket.
benzinga.com Rapport Therapeutics Prices Separate Offerings Of ~$175M Of Stock At $21.00/Share, Warrants To Purchase Up To ~$25M Of Stock At $20.999 Per Pre-Funded Warrant, And $150M Of 2.25% Convertible Senior Notes Due 2032 Concurrently with the underwritten offerings, Rapport entered into a share purchase agreement with a certain investor (the "Investor"), in a separately negotiated transaction (the "concurrent private
benzinga.com Why Ultra Clean Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Ultra Clean shares surged 14.6% after beating earnings and sales estimates; Ultralife soared 143.8% on a $320M acquisition deal.
benzinga.com Rapport Therapeutics (RAPP) Shares Sink 20% After Hours Rapport Therapeutics stock falls after hours as investors assess proposed stock and convertible notes offerings.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG)…
- benzinga.com Rapp Therapeutics Files For Offering Of Common Stock; Size Not Disclosed Common StockWe are offering $ of shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus.Our common stock is listed on The Nasdaq Global Market under the…
- benzinga.com Rapport Therapeutics Commences Separate Underwritten Public Offerings Of $200M Of Shares And $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2032 Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for…
- benzinga.com Jones Trading Maintains Buy on Rapport Therapeutics, Raises Price Target to $82 Jones Trading analyst Justin Walsh maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $50 to $82.
- benzinga.com Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $50 Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $51 to $50.
benzinga.com Guggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70 Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $70.
benzinga.com HC Wainwright & Co. Reiterates Buy on Rapport Therapeutics, Maintains $66 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $66 price target.
benzinga.com Why Is Rapport Therapeutics Stock Trading Higher Today? Rapport Therapeutics posts positive Phase 2 trial results for RAP-219 in acute bipolar mania, setting up Phase 3 studies in 2027.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
benzinga.com BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $89 BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $75 to $89.- benzinga.com Rapport Therapeutics Announces That Topline Results From Its Phase 2 Trial Of RAP-219 In Adults With Acute Bipolar Mania Met Primary Endpoint The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
- benzinga.com UBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71 UBS analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $71.
- benzinga.com Wolfe Research Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $50 Wolfe Research initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Outperform rating and announces Price Target of $50.